



Independent Assurance Statement

Growlity/AR/232415

Reporting Period – Apr 1st 2023 to Mar 31st 2024

To

Dr. Krishna Prasad Chigurupati,

Chairman & Managing Director of Granules India Limited (GIL).

2nd Floor, Block III,
My Home Hub, Madhapur, Hyderabad – 500081

Independent Assurance Report

Growlity, Inc. hereinafter referred as ("the Service Provider) was appointed by **Granules India Limited** hereinafter referred as ('the Company') to conduct a limited assurance engagement on the non-financial sustainability information in the Carbon Disclosure Report (CDP) 2024 and ESG KPI Roadmap 2030. The sustainability information adheres to the comprehensive guidelines set forth by the ISO 14064-1:2018 and Green House Gas Protocol, ensuring that the reported data aligns with globally recognized sustainability reporting frameworks.

Assurance Standard

The verification engagement has been planned and performed in accordance with the verification methodology developed by Growlity, which is based upon the "**AA1000 Assurance Standard (AA1000AS v3)**" also the verification process is carried out based principles and guidelines provided in **ISO 14064-3:2019 – "Specification with guidance for the verification and validation of greenhouse gas statements" standard** and **Global Reporting Initiative's (GRI) Universal Standards 2021** for validation of information mentioned in ESG KPI Roadmap 2030.

Scope of Assurance and Methodology

The Scope of our service for this assurance engagement was limited to review of below information pertaining to non-financial sustainability information of the company and as per the requirements of all data points for Carbon Disclosure Project (CDP) 2024 and

GROWLITY, INC.

575 FIFTH AVENUE, NEW YORK, NY 10017, USA

contact@growlity.com

www.growlity.com

sustainability information mentioned in ESG KPI Roadmap 2030.

- (C1) - Introduction - Total locations of the company and its non - financial information - **Annexure – II**
- (C2) - Identification, Assessment, and Management of Dependencies, Impact, Risk & Opportunities
- (C3) - Disclosure of Risk and Opportunities
- (C4) - Governance – Policies and Key Performance Indicators
- (C5) - Business Strategy – Transition Plan
- (C6) - Environmental Performance – Consolidated Approach
- (C7) - Environmental Performance – Climate Change – Location wise and category wise GHG emissions, Renewable energy generation & consumption - **Annexure – I**

The details of the subject matter are described in the annexures below:

Annexure – I – Environmental Performance – Climate Change – April 1st 2023 to March 31st 2024

Green House Gas Emissions (TCO₂Eq)			
Sr. No	Scope	Category	TCO₂Eq
1.	1	Direct emissions from sources owned or controlled by a company	58,254
2.	2	Conventional Electricity - Location based	63,078
3.		Conventional Electricity - Market based	<i>34,519</i>
Total Scope (1+2) – Location based			1,21,332
Total Scope (1+2) – Market based			92,773
4.	3	Purchased Goods & Services	5,19,808
5.		Capital Goods	28,830
6.		Fuel and Energy Related Activities	23,453
7.		Upstream Transportation & Distribution	8,640
8.		Waste Generated from Operations	3,721
9.		Business Travel	931
10.		Employee Commuting	2,089
11.		Upstream Leased Assets	7,781
12.		Downstream Transportation & Distribution	25,924
13.		Processing of Sold Products	41,188
14.		Use of Sold Products	-
15.		End of Life Treatment of sold products	4,330
16.		Downstream Leased Assets	-
17.		Franchises	-
18.	Investments	-	
Total Scope 3 (TCO₂Eq)			6,66,694

Avoided Green House Gas Emissions (TCO₂Eq)			
Sr. No	Scope	Category	TCO₂Eq
1.	2	Avoided through generation and consumption of Renewable Energy (PPA+ Onsite +I-RECs)	28,559

We conducted, on a sample basis, review and verification of data collection / calculation methodology and general review of the logic on inclusion / omission of necessary relevant information / data and this was limited to: remote verification of data, on a selective test basis, for the following units / locations, through consultations with the site team and sustainability team.

Execution of audit trail of claims and data streams, on a selective test basis, to determine the level of accuracy in collection, transcription and aggregation processes followed.

Review of Company's plans, policies and practices, pertaining to their Social, Environmental and Sustainable Development, to be able to make comments on the fairness of sustainability reporting.

Review of company's approach towards materiality assessment disclosed in the report to identify relevant issues.

Annexure – II - Locations Covered

Sr. No.	Locations	Address
1.	Head Office	2nd Floor, Block III, My Home Hub, Madhapur, Hyderabad – 500081
2.	Finished Dosage Unit	160/A, 161/E, 162 & 174/A, Gagillapur Village, Dundigal Gandimaisamma Mandal, Medchal-Malkajgiri District – 500 043, Telangana State, India.
3.	API Unit – I	Sy. No. 533, 535, 536, 537 Temple Road, Bonthapally Village, Gummadidala Mandal, Sangareddy District – 502 313, Telangana State, India.
4.	API Unit – II	Plot No. 15A/1, Phase III, IDA Jeedimetla, Qutubullapur Mandal, Medchal-Malkajgiri District, Hyderabad – 500 055, Telangana State, India.
5.	API Unit – III	Sy.No.216, Bonthapally Village, Gummadidala Mandal, Sangareddy District – 502 313, Telangana State, India.
6.	API Unit – IV	Plot No 8, J.N. Pharma City, Tadi Village, Parawada Mandal, Anakapalli District – 531 019, Andhra Pradesh, India.
7.	API Unit – V	Plot No. 30, J. N. Pharma City, Parawada Mandal, Anakapalli District – 531 019, Andhra Pradesh, India.
8.	R&D Centre 1	Plot No. 56, Road No. 5, ALEAP Industrial Area, Pragathi Nagar, Gajularamaram Village, Qutubullapur Mandal, Medchal-Malkajgiri District, Hyderabad – 500 072, Telangana State, India.

9.	R&D Centre 2	Survey Nos. 234/1 to 4 and 6 to 7, 235 /6 to 9 and 245/1 to 3, India Land Global Industrial Park, Hinjewadi Phase -1, Mulshi Taluka, Pune District – 411 057, Maharashtra State, India.
10.	R&D Centre 3	H.No.5-33, Sy No.352, Plot No. 8, Road No. 2, ALEAP Industrial Area, Pragathi Nagar, Gajularamaram village, Qutubullapur Mandal, Medchal- Malkajgiri District, Hyderabad – 500 072, Telangana State, India.
11.	R&D Centre 4	Lab No: 11 & 13, Building No:1800, Sy No. 101,101/2 & 340, M. N. Park, Genome Valley, Lalgadi Malakpet Village, Shameerpet Mandal, Medchal- Malkajgiri District, 500 078, Telangana State, India.
12.	Granules USA, Inc.	35 Waterview Blvd., 3rd Floor, Parsippany, NJ - 07054, USA.
13.	Granules Pharmaceuticals, Inc.	3701 Concorde Parkway, Chantilly, VA - 20151, USA
14.	Granules Life Sciences Private Limited	Sy.Nos. 325-326, 333- 336, 340-346 ,Lalgadimalakpet, Medcal- Malkajgiri district 500078,Telangana ,India
15.	Granules CZRO Private Limited	PLOT No. 120, 121(Part), Visakha Pharmacy Limited -SEZ, Jawaharlal Nehru Pharma City, Parwada Mandal, Anakapalle District, Andhra Pradesh, India.

Our Observations

The Company has demonstrated its commitment to sustainable development by reporting its performance on various material topics for the reporting period April 1st 2023 to March 31st 2024. Areas of further improvement wherever identified have been brought before the attention of the management of the company.

Conclusion

In our professional opinion, based on the procedure performed and evidence obtained, nothing has come to our attention that causes us to believe that the subject matter information is not prepared, in all material respects, in accordance with the standard and applicable criteria of AA1000AS v3.



Dr. Nitin Dumasia
President & CEO
Date: Aug 8th 2024
Place: New York, USA



AA1000
Licensed Assurance Provider
000-607



AA1000
Licensed Report
000-607/V3-5LXEG

GROWLITY, INC.

575 FIFTH AVENUE, NEW YORK, NY 10017, USA

contact@growlity.com

www.growlity.com